{"id":"F2018L00187","name":"Statement of Principles concerning Guillain-Barre syndrome (Reasonable Hypothesis) (No. 23 of 2018)","slug":"statement-of-principles-concerning-guillain-barre-syndrome-reasonable-hypothesis-no-23-of-2018","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":96806,"registerId":"commonwealth-F2018L00187-current","compilationNumber":null,"startDate":"2026-04-02","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Statement of Principles concerning Guillain-Barre syndrome (Reasonable Hypothesis) (No. 23 of 2018)","content":"![Commonwealth Coat of Arms](image.001.png)\n\nStatement of Principles concerning Guillain-Barre syndrome (Reasonable Hypothesis) (No. 23 of 2018)\n\nmade under subsection 196B(2) of the\n\nVeterans' Entitlements Act 1986\n\nCompilation No. 2\n\nCompilation date: 25 July 2022\n\nIncludes amendments up to: Amendment Statement of Principles concerning Guillain-Barre syndrome (Reasonable Hypothesis) (No. 74 of 2022) (F2022L00912)\n\nThe day of commencement of this Amendment Statement of Principles concerning Guillain-Barre syndrome is 25 July 2022.\n\nAbout this compilation\n\nThis compilation\n\nThis is a compilation of the Statement of Principles concerning Guillain-Barre syndrome (Reasonable Hypothesis) (No.23 of 2018) that shows the text of the law as amended and in force on 25 July 2022.\n\nThe notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.\n\nUncommenced amendments\n\nThe effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.\n\nApplication, saving and transitional provisions for provisions and amendments\n\nIf the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.\n\nModifications\n\nIf the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.\n\nSelf‑repealing provisions\n\nIf a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.\n\nContents\n\n1 Name\n\n3 Authority\n\n5 Application\n\n6 Definitions\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n8 Basis for determining the factors\n\n9 Factors that must exist\n\n10 Relationship to service\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nSchedule 1 - Dictionary\n\n1 Definitions\n\nEndnotes\n\nEndnote 1—About the endnotes\n\nEndnote 2—Abbreviation key\n\nEndnote 3—Legislation history\n\nEndnote 4—Amendment history\n\n  \n\n1 Name\n\nThis is the Statement of Principles concerning Guillain-Barre syndrome (Reasonable Hypothesis) (No. 23 of 2018).\n\n3 Authority\n\nThis instrument is made under subsection 196B(2) of the Veterans' Entitlements Act 1986.\n\n5 Application\n\nThis instrument applies to a claim to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 applies.\n\n6 Definitions\n\nThe terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n(1) This Statement of Principles is about Guillain-Barre syndrome and death from Guillain-Barre syndrome.\n\nMeaning of Guillain-Barre syndrome\n\n(2) For the purposes of this Statement of Principles, Guillain-Barre syndrome:\n\n(a) means an acute or subacute immune-mediated disorder of the peripheral nervous system producing symptoms and signs of impaired motor, sensory or autonomic functioning; and\n\n(b) includes:\n\n(i) acute inflammatory demyelinating polyneuropathy;\n\n(ii) acute motor axonal neuropathy;\n\n(iii) acute motor sensory axonal neuropathy;\n\n(iv) Miller Fisher syndrome; and\n\n(v) other variant forms of Guillain-Barre syndrome; and\n\n(c) excludes chronic inflammatory demyelinating polyneuropathy.\n\n> Note 1: The most common variant of Guillain-Barre syndrome is acute inflammatory demyelinating polyneuropathy, which is characterised by rapidly progressive symmetrical limb weakness, loss of tendon reflexes, mild sensory signs and variable autonomic dysfunction.\n\n> Note 2: The diagnosis of Guillain-Barre syndrome is normally confirmed by electrodiagnostic testing or elevated protein concentration in cerebrospinal fluid without an elevated white cell count (cytoalbuminologic dissociation).\n\n(3) While Guillain-Barre syndrome attracts ICD‑10‑AM code G61.0, in applying this Statement of Principles the meaning of Guillain-Barre syndrome is that given in subsection (2).\n\n(4) For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.\n\nDeath from Guillain-Barre syndrome\n\n(5) For the purposes of this Statement of Principles, Guillain-Barre syndrome, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's Guillain-Barre syndrome.\n\n> Note: terminal event is defined in the Schedule 1 – Dictionary.\n\n8 Basis for determining the factors\n\nThe Repatriation Medical Authority is of the view that there is sound medical‑scientific evidence that indicates that Guillain-Barre syndrome and death from Guillain-Barre syndrome can be related to relevant service rendered by veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA.\n\n> Note: MRCA, relevant service and VEA are defined in the Schedule 1 – Dictionary.\n\n9 Factors that must exist\n\nAt least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting Guillain-Barre syndrome or death from Guillain-Barre syndrome with the circumstances of a person's relevant service:\n\n(1) having an infection from the specified list of infections, where that infection has been acquired within the two months before the clinical onset of Guillain-Barre syndrome;\n\n> Note: specified list of infections is defined in the Schedule 1 - Dictionary.\n\n(2) being infected with human immunodeficiency virus at the time of the clinical onset of Guillain-Barre syndrome;\n\n(3) having a clinically apparent herpes zoster or herpes simplex infection in the two months before the clinical onset of Guillain-Barre syndrome;\n\n(4) having a symptomatic gastrointestinal or respiratory tract infection in the two months before the clinical onset of Guillain-Barre syndrome;\n\n(5) receiving a vaccine from the specified list of vaccines within the two months before the clinical onset of Guillain-Barre syndrome;\n\nNote: specified list of vaccines is defined in the Schedule 1 – Dictionary.\n\n(6) having a malignant neoplasm, other than non-melanotic malignant neoplasm of the skin, at the time of the clinical onset of Guillain-Barre syndrome;\n\n(7) having a solid organ or stem cell transplant before the clinical onset of Guillain-Barre syndrome;\n\n(8) having surgery requiring a general, spinal or epidural anaesthetic, within the two months before the clinical onset of Guillain-Barre syndrome;\n\n(9) being treated with a tumour necrosis factor-α inhibitor in the two months before the clinical onset of Guillain-Barre syndrome;\n\n(10) having systemic lupus erythematosus at the time of clinical onset of Guillain-Barre syndrome;\n\n(11) inability to obtain appropriate clinical management for Guillain-Barre syndrome.\n\n10 Relationship to service\n\n(1) The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.\n\n(2) The factor set out in subsection 9(11) applies only to material contribution to, or aggravation of, Guillain-Barre syndrome where the person's Guillain-Barre syndrome was suffered or contracted before or during (but did not arise out of) the person's relevant service.\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nIn this Statement of Principles:\n\n(1) if a factor referred to in section 9 applies in relation to a person; and\n\n(2) that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(2) of the VEA;\n\nthen the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.\n\nSchedule 1 \\- Dictionary\n\nNote: See Section 6\n\n1 Definitions\n\nIn this instrument:\n\nGuillain-Barre syndrome—see subsection 7(2).\n\nMRCA means the Military Rehabilitation and Compensation Act 2004.\n\nrelevant service means:\n\n(a) operational service under the VEA;\n\n(b) peacekeeping service under the VEA;\n\n(c) hazardous service under the VEA;\n\n(d) British nuclear test defence service under the VEA;\n\n(e) warlike service under the MRCA; or\n\n(f) non-warlike service under the MRCA.\n\n> Note: MRCA and VEA are also defined in the Schedule 1 - Dictionary.\n\nspecified list of infections means:\n\n(a) Campylobacter jejuni;\n\n(b) Chikungunya virus;\n\n(c) cytomegalovirus;\n\n(d) dengue virus;\n\n(e) Epstein-Barr virus;\n\n(f) Haemophilus influenzae;\n\n(g) hepatitis A virus;\n\n(h) hepatitis B virus;\n\n(i) hepatitis E virus;\n\n(j) influenza virus;\n\n(k) Japanese encephalitis virus;\n\n(l) measles virus;\n\n(m) Mycoplasma pneumoniae;\n\n(n) Orientia tsutsugamushi (scrub typhus);\n\n(o) parvovirus B19;\n\n(oa) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2);\n\n(p) West Nile virus; or\n\n(q) Zika virus.\n\n> Note: SARS-CoV-2 is the virus which causes coronavirus disease 2019 (COVID-19).\n\nspecified list of vaccines means:\n\n(a) coronavirus disease 2019 (COVID-19) vaccine;\n\n(b) influenza vaccine; or\n\n(c) nerve tissue derived rabies vaccine.\n\nterminal event means the proximate or ultimate cause of death and includes the following:\n\n(a) pneumonia;\n\n(b) respiratory failure;\n\n(c) cardiac arrest;\n\n(d) circulatory failure; or\n\n(e) cessation of brain function.\n\nVEA means the Veterans' Entitlements Act 1986.\n\n> Note: Endnotes\n\n> Note: Endnote 1—About the endnotes\n\nThe endnotes provide information about this compilation and the compiled law.\n\nThe following endnotes are included in every compilation:\n\nEndnote 1—About the endnotes\n\nEndnote 2—Abbreviation key\n\nEndnote 3—Legislation history\n\nEndnote 4—Amendment history\n\nAbbreviation key—Endnote 2\n\nThe abbreviation key sets out abbreviations that may be used in the endnotes.\n\nLegislation history and amendment history—Endnotes 3 and 4\n\nAmending laws are annotated in the legislation history and amendment history.\n\nThe legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.\n\nThe amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.\n\nMisdescribed amendments\n\nA misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.\n\nIf a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.\n\n> Note: Endnote 2—Abbreviation key\n\n|                                                | o = order(s)                        |\n| ---------------------------------------------- | ----------------------------------- |\n| ad = added or inserted                         | Ord = Ordinance                     |\n| am = amended                                   | orig = original                     |\n| amdt = amendment                               | par = paragraph(s)/subparagraph(s)  |\n| c = clause(s)                                  | /sub‑subparagraph(s)                |\n| C[x] = Compilation No. x                       | pres = present                      |\n| Ch = Chapter(s)                                | prev = previous                     |\n| def = definition(s)                            | (prev…) = previously                |\n| Dict = Dictionary                              | Pt = Part(s)                        |\n| disallowed = disallowed by Parliament          | r = regulation(s)/rule(s)           |\n| Div = Division(s)                              |                                     |\n| exp = expires/expired or ceases/ceased to have | reloc = relocated                   |\n| effect                                         | renum = renumbered                  |\n| F = Federal Register of Legislation            | rep = repealed                      |\n| gaz = gazette                                  | rs = repealed and substituted       |\n| LA = Legislation Act 2003                      | s = section(s)/subsection(s)        |\n| LIA = Legislative Instruments Act 2003         | Sch = Schedule(s)                   |\n| (md) = misdescribed amendment can be given     | Sdiv = Subdivision(s)               |\n| effect                                         | SLI = Select Legislative Instrument |\n| (md not incorp) = misdescribed amendment       | SR = Statutory Rules                |\n| cannot be given effect                         | Sub‑Ch = Sub‑Chapter(s)             |\n| mod = modified/modification                    | SubPt = Subpart(s)                  |\n| No. = Number(s)                                | underlining = whole or part not     |\n|                                                | commenced or to be commenced        |\n\n> Note: Endnote 3—Legislation history\n\n| Name                                                                                                          | Registration             | Commencement | Application, saving and transitional provisions |\n| ------------------------------------------------------------------------------------------------------------- | ------------------------ | ------------ | ----------------------------------------------- |\n| Statement of Principles concerning Guillain-Barre syndrome (Reasonable Hypothesis) (No. 23 of 2018)           | 5 March 2018F2018L00187  | 2 April 2018 |                                                 |\n| Amendment Statement of Principles concerning Guillain-Barre syndrome (Reasonable Hypothesis) (No. 57 of 2021) | 23 April 2021F2021L00483 | 24 May 2021  |                                                 |\n| Amendment Statement of Principles concerning Guillain-Barre syndrome (Reasonable Hypothesis) (No. 74 of 2022) | 30 June 2022F2022L00912  | 25 July 2022 |                                                 |\n\n> Note: Endnote 4—Amendment history\n\n| Provision affected                                            | How affected      |\n| ------------------------------------------------------------- | ----------------- |\n| Section 2……………….                                              | rep LA s 48D      |\n| Section 4……………….                                              | rep LA s 48C      |\n| Subsection 9(1)……..…                                          | am No. 57 of 2021 |\n| Schedule 1 – Dictionary – specified list of infections………………. | am No. 57 of 2021 |\n| Subsection 9(5)………..                                          | rs No. 74 of 2022 |\n| Schedule 1 – Dictionary – specified list of vaccines………………..  | rs No. 74 of 2022 |","sortOrder":0}],"analysis":{"flash_summary_failed":{"failed":true,"reason":"Unauthenticated. Configure AI_GATEWAY_API_KEY or use a provider module. Learn more: https://ai-sdk.dev/unauthenticated-ai-gateway","source":"analysis-cron"},"flash_summary":{"complexity_score":3,"scope_assessment":{"changed":true,"description":"The instrument has been expanded since the original 2018 version by amendments that broaden the enumerated infectious agents and vaccines that can, as a minimum, raise a reasonable hypothesis. Notably, Amendment No. 57 of 2021 updated the specified list of infections to include SARS‑CoV‑2 and amended subsection 9(1), and Amendment No. 74 of 2022 changed subsection 9(5) and the specified list of vaccines to include COVID‑19 vaccine (see endnotes and Schedule). These updates increase the range of medical events that can trigger the reasonable‑hypothesis pathway for entitlement claims—an expansion consistent with the instrument's original mechanism (listing causal factors) but materially broader in the set of contemporary pathogens and vaccines covered."},"complexity_factors":["Short instrument (11 substantive sections plus a Schedule)","One main defined term block in Schedule 1 with about 6 key definitions (MRCA, VEA, relevant service, specified lists, terminal event, Guillain‑Barre syndrome)","Specified list of infections contains ~21 items (nested items including SARS‑CoV‑2), increasing factual detail","Specified list of vaccines contains 3 items (including COVID‑19 vaccine) — factual expansion","Repeated conditional timing: multiple factors require occurrence within two months before clinical onset (sections 9(1), 9(3), 9(4), 9(5), 9(8), 9(9))","Cross‑references to other statutes and SoPs (subsection 196B(2) VEA, sections 120A VEA and 338 MRCA, and other Statements of Principles under section 11)","Limited but important exception/qualification in section 10(2) for factor 9(11) (inability to obtain clinical management)","Reference to clinical diagnostic standards (ICD‑10‑AM) but with textual override (section 7(3)–(4))"],"plain_english_summary":"**What this document is and what it does**\n\n- This is a Statement of Principles (SoP) made under the Veterans' Entitlements Act 1986. It is used to decide whether Guillain‑Barre syndrome (GBS) or death from GBS can be connected, on a \"reasonable hypothesis\", to a person's military or relevant service for the purpose of veterans' entitlements and military compensation claims (see sections 3 and 5).\n\n- Mechanically, the SoP does two main things:\n  - It defines what is meant by \"Guillain‑Barre syndrome\" for claims purposes (including major variants but excluding chronic inflammatory demyelinating polyneuropathy) and clarifies diagnostic reference points (section 7).\n  - It lists the specific factors that, if present, are sufficient as a minimum to raise a reasonable hypothesis that a person's GBS (or death contributed to by GBS) is related to their relevant service (section 9). If at least one of those factors existed in relation to the person, and the factor is shown to be related to their relevant service, the legal threshold of a \"reasonable hypothesis\" is met (sections 9 and 10).\n\n**Who is affected**\n\n- Claimants: veterans, former members of the Forces and members of Peacekeeping Forces who lodge claims under the VEA or the Military Rehabilitation and Compensation Act (MRCA) for GBS or death from GBS (application described in section 5 and \"relevant service\" defined in the Schedule).\n\n- The Department/Authority: the Repatriation Medical Authority (RMA) provides the medical-scientific basis for the SoP and decision-makers in the Department of Veterans' Affairs use the SoP to assess claims. The outcome determines entitlement to benefits or compensation.\n\n**What factors the SoP lists (practical summary)**\n\n- A claimant raises a reasonable hypothesis linking GBS to service if at least one of the following applied, and that factor is connected to the person's relevant service (section 9 and section 10):\n  - Infection from a specified list acquired within two months before GBS onset (the Schedule lists pathogens such as Campylobacter jejuni, cytomegalovirus, influenza, and SARS‑CoV‑2, among others) (section 9(1) and Schedule).\n  - HIV infection present at the time of GBS onset (section 9(2)).\n  - Clinically apparent herpes zoster or herpes simplex infection in the two months before onset (section 9(3)).\n  - Symptomatic gastrointestinal or respiratory infection in the two months before onset (section 9(4)).\n  - Receipt of a vaccine from the specified vaccine list within two months before onset (the Schedule lists COVID‑19 vaccine, influenza vaccine, and nerve tissue–derived rabies vaccine) (section 9(5) and Schedule).\n  - Presence of a malignant neoplasm (except non‑melanotic skin cancer) at the time of onset (section 9(6)).\n  - Solid organ or stem cell transplant before onset (section 9(7)).\n  - Recent surgery under general, spinal or epidural anaesthetic within two months before onset (section 9(8)).\n  - Treatment with a tumour necrosis factor‑α inhibitor in the two months before onset (section 9(9)).\n  - Systemic lupus erythematosus at the time of onset (section 9(10)).\n  - Inability to obtain appropriate clinical management for GBS (section 9(11)), but this factor is limited: it only applies to material contribution or aggravation where the GBS was suffered or contracted before or during (but did not arise out of) relevant service (see section 10(2)).\n\n- The SoP also requires that if one of the listed factors refers to an injury or disease that itself is covered by another SoP, the factors in that other SoP apply as they are in force (section 11).\n\n**Why this matters in practice**\n\n- Evidentiary threshold: The SoP sets a clear, narrow set of medical events and time windows (notably two months for many items) that can, as a minimum, establish a reasonable link between GBS and service. Decision-makers use this to decide whether to accept causation for entitlement purposes (sections 8–10).\n\n- Who gains and who bears costs: Claimants who can document one of the listed infections, vaccines, medical conditions or events within the specified timing are advantaged because the SoP supplies an evidentiary route to meet the reasonable‑hypothesis threshold. Claimants without those listed factors may need other evidence to meet the same threshold, which can increase the time and cost of proving a claim (see section 9).\n\n- Administrative and compliance effects: The instrument creates predictable rules but requires claimants (and the Department) to obtain medical records, laboratory or vaccination records, and clinical evidence to demonstrate timing and relation to service. That imposes compliance costs on claimants and evidentiary work on decision-makers (implication of sections 7, 9 and Schedule definitions).\n\n- Interaction with other SoPs and medical science: The SoP expressly cross‑references other SoPs when relevant (section 11) and relies on the RMA's assessment of sound medical‑scientific evidence (section 8). This creates potential points of interaction and interpretive questions where multiple SoPs or emerging medical evidence (for example, new pathogens or vaccines) are relevant.\n\n**Implementation risks and practical trade‑offs**\n\n- Timing disputes: Many listed factors are limited to events in the two months before clinical onset; disputes may arise over the exact clinical onset date and the timing of infections or vaccinations (section 9).\n\n- Evidence quality: The SoP's usefulness depends on the availability and quality of clinical, laboratory and vaccination records. Where records are incomplete, claimants may struggle to meet the SoP's straightforward criteria.\n\n- Scope changes over time: The Schedule can be updated (for example, it now includes SARS‑CoV‑2 and COVID‑19 vaccine). Updates expand or contract the set of events that can raise a reasonable hypothesis and so affect the volume and type of claims (see Schedule and endnotes about amendments).\n\n**Key legal cross‑references and definitions to note**\n\n- \"Relevant service\" is defined in the Schedule and includes several categories under the VEA and MRCA (Schedule—definitions).\n- \"Terminal event\" is defined in the Schedule for assessing deaths contributed to by GBS (Schedule—definitions).\n- The SoP refers to the ICD‑10‑AM code for GBS but makes the statutory textual definition the operative meaning for claims assessment (section 7(3)–(4).\n\n(References in parentheses are to sections and Schedule items of the Statement of Principles.)"},"kimi_summary":{"content_quality":"ok","complexity_score":4,"scope_assessment":{"changed":false,"description":"The legislation maintains its original narrow scope. It was always intended to establish the medical causation rules specifically for Guillain-Barre syndrome under the veterans' compensation framework. The 2021 and 2022 amendments merely updated the scientific lists (adding COVID-19 related factors) without expanding the instrument's purpose or jurisdictional reach. The core mechanism — listing specific infections, vaccines, and medical events as reasonable hypothesis triggers — remains unchanged from the 2018 original."},"complexity_factors":["Moderate cross-referencing: Requires reference to the Veterans' Entitlements Act 1986 and Military Rehabilitation and Compensation Act 2004 for definitions of service types","11 distinct causal factors with varying temporal windows (mostly 2-month lookback periods, some 'at time of onset' requirements)","Nested definitions: 'Specified list of infections' contains 17 specific pathogens including technical names (e.g., Orientia tsutsugamushi) and lay explanations (e.g., 'scrub typhus')","Conditional logic in section 10(2): Factor 9(11) has restricted application only to aggravation cases where GBS pre-existed service","Section 11 creates dynamic incorporation by reference — other Statements of Principles apply 'as in force from time to time', creating moving regulatory targets","Medical terminology requiring specialist knowledge: ICD-10-AM coding, electrodiagnostic criteria, cytoalbuminologic dissociation","Dual statutory framework: Must be read against both VEA and MRCA compensation schemes simultaneously"],"plain_english_summary":"This Statement of Principles sets the medical test for when veterans and defence members can get compensation for Guillain‑Barré syndrome (GBS). It creates a \"reasonable hypothesis\" standard: if a claimant had one of several listed risk factors (e.g., recent infections or specific vaccines, surgery, transplant, cancer, immunosuppression, or lack of care) that can be tied to service, service is presumed to have contributed. The 2022 update added SARS‑CoV‑2 infection and COVID‑19 vaccines."}},"importantCases":[],"_links":{"self":"/api/acts/statement-of-principles-concerning-guillain-barre-syndrome-reasonable-hypothesis-no-23-of-2018","history":"/api/acts/statement-of-principles-concerning-guillain-barre-syndrome-reasonable-hypothesis-no-23-of-2018/history","analysis":"/api/acts/statement-of-principles-concerning-guillain-barre-syndrome-reasonable-hypothesis-no-23-of-2018/analysis","conflicts":"/api/acts/statement-of-principles-concerning-guillain-barre-syndrome-reasonable-hypothesis-no-23-of-2018/conflicts","importantCases":"/api/acts/statement-of-principles-concerning-guillain-barre-syndrome-reasonable-hypothesis-no-23-of-2018/important-cases","documents":"/api/acts/statement-of-principles-concerning-guillain-barre-syndrome-reasonable-hypothesis-no-23-of-2018/documents"}}